Trial Profile
Treatment of rheumatoid Arthritis with an anti-tumor necrosis factor agent or tocilizumab as First Biologic therapy in a global comparative observational study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Feb 2016
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 08 Feb 2016 New trial record